Outlook Therapeutics Inc OTLK
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-06-13 |
| Shares Out. | 187,000,000 |
| Website | outlooktherapeutics.com/ ↗ |
| Phone | 16096193990 |
| Employees | 17 |
| Revenue | $8,700 |
| Gross Profit | -$8,265 |
| Net Income | -$20.3M |
| Free Cash Flow | -$56.2M |
| Total Assets | $26.2M |
| Total Liabilities | $36.6M |
| Equity | -$10.4M |
About Outlook Therapeutics Inc
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics Inc is a publicly traded company under the ticker symbol OTLK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)